JPH0476972B2 - - Google Patents
Info
- Publication number
- JPH0476972B2 JPH0476972B2 JP62192307A JP19230787A JPH0476972B2 JP H0476972 B2 JPH0476972 B2 JP H0476972B2 JP 62192307 A JP62192307 A JP 62192307A JP 19230787 A JP19230787 A JP 19230787A JP H0476972 B2 JPH0476972 B2 JP H0476972B2
- Authority
- JP
- Japan
- Prior art keywords
- drug
- weight
- parts
- water
- licorice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 claims description 56
- 229940079593 drug Drugs 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 20
- 241000411851 herbal medicine Species 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 9
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 9
- 229940010454 licorice Drugs 0.000 claims description 9
- 241000202807 Glycyrrhiza Species 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims 3
- 235000017443 Hedysarum boreale Nutrition 0.000 claims 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 201000006549 dyspepsia Diseases 0.000 description 10
- 208000024798 heartburn Diseases 0.000 description 10
- 208000007882 Gastritis Diseases 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 229940126585 therapeutic drug Drugs 0.000 description 8
- 230000037213 diet Effects 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 230000003340 mental effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 208000007107 Stomach Ulcer Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002386 leaching Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 206010028813 Nausea Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 208000000718 duodenal ulcer Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 230000008693 nausea Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 235000011511 Diospyros Nutrition 0.000 description 4
- 208000004232 Enteritis Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001839 endoscopy Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 244000236655 Diospyros kaki Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000009207 exercise therapy Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010000084 Abdominal pain lower Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000030135 gastric motility Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000723267 Diospyros Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000008214 highly purified water Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000000948 sympatholitic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
【発明の詳細な説明】
[産業上の利用分野]
この発明は、胃腸病治療薬およびその製造方法
に関し、特にエキス剤の形の胃腸病治療薬および
その製造方法に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to a therapeutic agent for gastrointestinal diseases and a method for producing the same, and particularly to a therapeutic agent for gastrointestinal diseases in the form of an extract and a method for producing the same.
[発明の背景]
一般に、下痢、便秘、悪心、嘔吐、胸やけ、胃
痛、腹痛といつた日常よく経験される消化管症状
は、消化液分泌機能と消化管運動機能の異常によ
つて起こることが多く、また消化管疾患の中で重
要な位置にある胃・十二脂腸潰瘍や潰瘍性大腸炎
およびびらん性胃炎などの疾患は、上記の機能の
ほかに、消化管の免疫機能およびこれら3つの機
能を維持するのに必要な血液循環機能の調節異常
に関係して発生し、これらの消化管機能は中枢神
経系に密接して支配を受けているために、上記の
ような症状および疾患は様々なストレスや心因的
な影響を強く受けて引起こされる。[Background of the Invention] In general, gastrointestinal symptoms commonly experienced on a daily basis, such as diarrhea, constipation, nausea, vomiting, heartburn, stomach pain, and abdominal pain, are caused by abnormalities in the digestive juice secretion function and gastrointestinal motility function. In addition to the above-mentioned functions, diseases such as gastric and duodenal ulcers, ulcerative colitis, and erosive gastritis, which are important among gastrointestinal diseases, are caused by the immune function of the gastrointestinal tract and these diseases. It occurs in connection with dysregulation of the blood circulation function necessary to maintain these three functions, and because these gastrointestinal functions are closely controlled by the central nervous system, the above symptoms and Diseases are caused by various stresses and strong psychological influences.
そこで、ストレスなどの心因的な要因によつて
生じる前記のような疾病を治療するに当つては、
ストレスなどの心因性病因の排除と適正な食事療
法に留意しながら、制酸剤、消化酵素剤、苦味
剤、鎮痙剤、あるいはこれらを配合した健胃消化
剤、胃液分泌や胃の運動を亢進させて食欲の増進
をはかる副交感神経刺激剤と交感神経抑制剤、制
酸剤と副交感神経遮断剤によつて胃液分秘や胃の
運動を中和し、抑制する潰瘍治療薬、および安中
散のような漢方薬による内科的な薬物療法が採用
されている。 Therefore, when treating the above-mentioned diseases caused by psychological factors such as stress,
While taking into account the elimination of psychogenic causes such as stress and appropriate dietary therapy, antacids, digestive enzymes, bittering agents, antispasmodics, or gastric digestive aids containing these, which enhance gastric juice secretion and gastric motility. A parasympathomimetic agent and a sympatholytic depressant that stimulate appetite and increase appetite, an ulcer treatment drug that neutralizes and suppresses gastric secretion and gastric motility through antacids and parasympathetic nerve blockers, and Anchusan. Internal medicine therapy using Chinese herbal medicines such as
しかしながら、上記の薬物療法において使用さ
れる薬剤が化学的に製剤されたものであるときに
は、消化管の病気あるいは症状が単純で軽けれ
ば、かなりの治療効果をあげることができるけれ
ども、前記病気あるいは症状が重かつたり、ある
いはそれが複合していると、満足な薬効が得られ
なかつたり、あるいは一時的に治つても病気の再
発を招く上に、様々な副作用を伴う傾向があり、
また前記薬剤が安中散のように薬用植物のみから
製剤されたものであるときには、副作用を生じる
おそれはないものの、治療効果が十分に得られな
いという問題があつた。 However, when the drugs used in the above drug therapy are chemically prepared, they can be highly effective in treating gastrointestinal diseases or symptoms if they are simple and mild; If the symptoms are severe or in combination, satisfactory drug effects may not be obtained, or even if the disease is temporarily cured, the disease may recur, and it tends to be accompanied by various side effects.
Furthermore, when the drug is prepared only from medicinal plants, such as Annachusan, there is a problem in that although there is no risk of side effects occurring, a sufficient therapeutic effect cannot be obtained.
[研究に基ずく知見事項]
そこで、本発明者は、このような状況に鑑みて
種々研究を重ねた結果、
(1) カキドウシ(生薬名、連銭草):3〜30重量
部と、
カンゾウ(同、甘草):2.5〜25重量部との配
合割合の生薬から抽出された生薬エキスを含む
水剤、散剤、顆粒剤、丸剤、錠剤、およびカプ
セル剤等の種々の製剤は、速やかに胃痛、腹
痛、腹部膨満感、下痢、便秘、悪心、嘔吐、胸
やけ、食欲不振等の症状を対症的に治癒させる
ばかりでなく、様々な胃腸病において著しい抗
潰瘍性、抗ストレス性および消炎作用を発揮
し、もつて継続的な服用により、胃腸潰瘍部で
肉芽の増殖を促すとともに消化管内壁面の炎症
を静めて、胃腸病、特にストレスに起因する胃
炎、腸炎および胃・十二脂腸潰瘍の自然治癒を
導き、しかも長期間服用しても副作用を全く起
こさないこと、および
(2) このような薬効を有する胃腸病治療薬は、特
に、前記配合割合の生薬を300〜900重量部の水
とともに加熱煮沸して前記生薬の有効成分を熱
湯中に浸出させながら、その浸出液を、前記水
の量がほぼ半量以下ないし6分の1となるまで
蒸発濃縮した後、このようにして得られた濃縮
液、すなわち生薬エキスを含む濃厚液を製剤す
ることによつて製造できること、
を見出した。[Findings based on research] Therefore, in view of the above situation, the present inventor conducted various studies and found that (1) Kakidou (herbal medicine name: Renzengusa): 3 to 30 parts by weight, and licorice. (Same, Licorice): Various preparations such as solutions, powders, granules, pills, tablets, and capsules containing crude drug extracts extracted from crude drugs at a blending ratio of 2.5 to 25 parts by weight should be promptly released. Not only does it symptomatically cure symptoms such as stomach pain, abdominal bloating, diarrhea, constipation, nausea, vomiting, heartburn, and loss of appetite, but it also has remarkable anti-ulcer, anti-stress, and anti-inflammatory effects in various gastrointestinal diseases. With continuous use, it promotes the proliferation of granulation in the gastrointestinal ulcer area and calms inflammation on the inner wall of the gastrointestinal tract, thereby preventing gastrointestinal diseases, especially stress-induced gastritis, enteritis, and gastric and duodenal ulcers. (2) A drug for treating gastrointestinal diseases with such medicinal effects is particularly effective if it contains 300 to 900 parts by weight of herbal medicines in the above-mentioned proportions. The active ingredients of the herbal medicine are leached into the boiling water by heating and boiling with water, and the leached liquid is evaporated and concentrated until the amount of the water becomes approximately half or less to one-sixth. It has been found that the present invention can be produced by preparing a concentrated liquid containing a herbal medicine extract, that is, a concentrated liquid containing a crude drug extract.
[発明の目的および構成]
この発明は、上記知見に基づいて発明されたも
ので、胃腸病、特にストレスに起因する胃炎と腸
炎および胃・十二脂腸潰瘍に対してすぐれた薬効
を発揮し、かつ長期間の服用によつても副作用が
皆無である胃腸病治療薬およびその製造方法を提
供することを目的とし、
(1) 前記配合割合の生薬から抽出された生薬エキ
スを有効成分として含有する胃腸病治療薬、お
よび
(2) 前記配合割合の生薬を300〜900重量部の水と
ともに加熱煮沸して前記生薬の有効成分を熱湯
中に浸出させながら、その浸出液を、前記水の
量がほぼ半量以下ないし6分の1となるまで蒸
発濃縮した後、このようにして得られた濃縮液
を製剤することを特徴とする前記胃腸病治療薬
の製造方法、
に係るものである。[Objective and Structure of the Invention] This invention was invented based on the above knowledge, and exhibits excellent medicinal efficacy against gastrointestinal diseases, particularly gastritis and enteritis caused by stress, and gastric and duodenal ulcers. The purpose of this drug is to provide a drug for treating gastrointestinal diseases that has no side effects even when taken for a long period of time, and a method for producing the same. and (2) heating and boiling the herbal medicine in the above-mentioned mixing ratio with 300 to 900 parts by weight of water to leach the active ingredients of the herbal medicine into the boiling water, and then pouring the leached liquid into the boiling water. This method relates to the method for producing a therapeutic drug for gastrointestinal diseases, which comprises evaporating and concentrating the product to approximately half or less to one-sixth of its volume, and then formulating the thus obtained concentrate.
[発明の具体的な説明]
1 生薬の配合割合
この発明において使用する生薬は、いずれも通
常の乾燥した状態で市場に供給されるものを指し
ており、したがつて、この発明において規定した
これらの生薬の配合割合はこのように乾燥した状
態にある生薬の重量に基づくものである。[Specific Description of the Invention] 1. Compounding ratio of crude drugs The crude drugs used in this invention refer to those that are normally supplied to the market in a dry state, and therefore, these prescribed in this invention are The blending ratio of the herbal medicine is based on the weight of the herbal medicine in a dry state.
この発明においては、カキドウシ:カンゾウの
配合割合が3〜30重量部:2.5〜25重量部の範囲
を外れると、胃腸病の治療において所望の効果が
あがらないとこから、これらの生薬の重量に基づ
く配合割合を上記のとおりに定めた。 In this invention, if the blending ratio of persimmon: licorice falls outside the range of 3 to 30 parts by weight: 2.5 to 25 parts by weight, the desired effect will not be achieved in the treatment of gastrointestinal diseases. The blending ratio was determined as above.
重量部で表わしたこの配合割合は、さらに9〜
16:7.5〜13であるのが好ましく、特にほぼ12:
10であるのが最も好ましい。 This blending ratio expressed in parts by weight is further 9 to 9.
Preferably 16:7.5-13, especially approximately 12:
Most preferably it is 10.
2 製剤の種類
この発明の胃腸病治療薬は、生薬エキスを含む
前記濃縮液自体の形であつてもよいことは勿論で
あるが、前記配合割合の生薬から抽出された生薬
エキスの効力を害わずに、これを有効成分として
含有すれば、水剤、散剤、顆粒剤、丸剤、錠剤、
またはカプセル剤のような、どのような形のもの
に製剤してもよく、そのためには従来の製剤にお
いて使用されていた添加物、例えば水、乳糖、ブ
ドウ糖、澱粉のような賦形剤、アラビアゴム、ゼ
ラチン、アルコールのような結合剤、または澱
粉、寒天末、CMCのような崩壊剤を適宜配合す
ることができるが、賦形剤として澱粉および乳糖
を加えたものが特に好ましい。2 Types of Preparation The therapeutic drug for gastrointestinal diseases of the present invention may of course be in the form of the concentrate itself containing the herbal medicine extract, but it may also be harmful to the efficacy of the herbal medicine extract extracted from the herbal medicine in the above-mentioned mixing ratio. If it contains this as an active ingredient, it can be used as a solution, powder, granule, pill, tablet, etc.
or capsules, for which additives used in conventional formulations, such as water, excipients such as lactose, glucose, starch, Arabic A binder such as rubber, gelatin, or alcohol, or a disintegrant such as starch, agar powder, or CMC may be appropriately blended, but those containing starch and lactose as excipients are particularly preferred.
3 生薬エキスの浸出および浸出液の濃縮
この発明において利用する生薬エキスは、前記
配合割合の生薬を300〜900重量部、好ましくは
500〜700重量部、そして最も好ましくは600重量
部の水とともに加熱煮沸し、かつそれによつて生
ずる浸出液を、水の量がほぼ半量以下ないし6分
の1、好ましくはほぼ半量以下ないし4分の1、
そして最も好ましくはほぼ3分の1となるまで蒸
発濃縮することによつて得られる濃縮液の形に調
製する点に重要であり、水の配合割合および浸出
液の濃縮程度のいずれかが上記の範囲から外れる
と、生薬エキスの抽出が十分でなかつたり、ある
いは有効成分の破壊が進行して所望の薬効を有す
る胃腸病治療薬を得ることができなくなることか
ら、この発明では水の配合割合および浸出液の濃
縮程度を上記のように定めた。3. Leaching of the crude drug extract and concentration of the leaching liquid The crude drug extract used in this invention contains 300 to 900 parts by weight of the crude drug at the above-mentioned mixing ratio, preferably
The resulting leachate is heated and boiled with 500 to 700 parts by weight, and most preferably 600 parts by weight, of water, and the resulting leachate is reduced to approximately half to one-sixth, preferably approximately half to one-fourth, of the amount of water. 1,
Most preferably, it is important to prepare it in the form of a concentrated liquid obtained by evaporating and concentrating it to about one-third, and either the blending ratio of water or the degree of concentration of the leachate is within the above range. If it deviates from the above, the crude drug extract may not be extracted sufficiently or the active ingredients may be destroyed, making it impossible to obtain a gastrointestinal disease treatment with the desired medicinal effect. The degree of enrichment was determined as above.
したがつて、この発明の胃腸病治療薬を製造す
るに当つては、カキドウシ:12重量部およびカン
ゾウ:10重量部を600重量部の水とともに加熱煮
沸して前記生薬の有効成分を熱湯中に浸出させな
がら、その浸出液を、前記水の量がほぼ3分の1
となるまで蒸発濃縮するのが最も好ましい。 Therefore, in producing the drug for treating gastrointestinal diseases of the present invention, 12 parts by weight of persimmons and 10 parts by weight of licorice are heated and boiled with 600 parts by weight of water, and the active ingredients of the herbal medicines are added to the boiling water. While leaching, the amount of water is approximately 1/3 of the amount of water.
It is most preferable to evaporate and concentrate until .
なお、浸出剤として使用する水は蒸留水または
脱イオン水のような純度の高い水が好ましく、ま
た「水の量がほぼ半量以下ないし6分の1となる
まで蒸発濃縮する」とは、浸出液の蒸発濃縮中に
簡単な方法、例えば、目分量やその他の簡単な方
法、例えば煮沸釜の内壁に印した目盛または煮沸
釜の外側に取り付けた液面計によつて、水の量が
半分以下ないし6分の1に減つたと認めることが
できる状態まで蒸発濃縮することを意味してい
る。 The water used as a leaching agent is preferably highly purified water such as distilled water or deionized water, and "evaporating and concentrating until the amount of water is approximately half or less to one-sixth" refers to the leaching solution. During the evaporation and concentration of water, the amount of water can be reduced to less than half by measuring by eye or by other simple methods, such as a scale marked on the inner wall of the boiling pot or a level gauge attached to the outside of the boiling pot. It means to evaporate and concentrate to a state where it can be recognized that the amount has been reduced to one to six times.
上記の生薬エキスを含む濃縮液は、前述のとお
り、その後種々の製剤法によつてこの発明の胃腸
病治療薬とすることができるが、前記濃縮液から
例えば濾過によつて生薬残渣を除去した濃厚液か
らなる水薬、あるいはその濃厚液を減圧釜に入れ
て、減圧下に温度:60〜70℃程度で前記濃厚液を
さらにペースト状の状態まで濃縮していく間に所
定量の賦形剤を加えて撹拌しながら粘土状の混合
物を形成させ、ついでこれを製粒機により顆粒状
に成形した後、乾燥することによつて調製した顆
粒剤の形で利用するのが特に好ましい。 As mentioned above, the concentrate containing the herbal medicine extract can be used as the gastrointestinal disease therapeutic agent of the present invention by subsequently applying various formulation methods. A liquid medicine consisting of a concentrated liquid or the concentrated liquid is placed in a vacuum pot, and the concentrated liquid is further concentrated to a paste-like state under reduced pressure at a temperature of about 60 to 70°C, while a predetermined amount of excipients are added. It is particularly preferred to use the mixture in the form of granules prepared by adding the agent and stirring to form a clay-like mixture, which is then formed into granules using a granulator and then dried.
[実施例および実施例に基く効果] ついで、この発明を実施例によつて説明する。[Examples and effects based on the examples] Next, the present invention will be explained by way of examples.
まず、生薬としてカキドウシとカンゾウを、ま
た浸出剤として蒸留水を用意した。 First, we prepared persimmon and licorice as herbal medicines, and distilled water as an infusion agent.
ついで、カキドウシ:12Kg、カンゾウ:10Kgお
よび蒸留水:600を煮沸釜に装入して加熱煮沸
し、それによつて蒸留水中に前記生薬のエキスを
浸出させながら、その浸出液を、前記蒸留水の量
がほぼ3分の1となるまで蒸発濃縮した。 Next, 12 kg of persimmon, 10 kg of licorice, and 600 g of distilled water were charged into a boiling pot and heated to boil, thereby leaching the extract of the herbal medicine into the distilled water. It was evaporated and concentrated until it was reduced to approximately one third.
つぎに、このように濃縮した浸出液を冷却後濾
過することによつて生薬残渣を除去し、その濾液
を減圧釜に投入して、これを適宜撹拌しながら減
圧下に温度:60〜70℃でさらに濃縮していく間に
賦形剤としてコーンスターチ:4.5Kgおよび乳
糖:200gを加えて粘土状の混合物を形成させた
後、粘土状混合物を製粒機により顆粒状に成形し
た。 Next, the crude drug residues are removed by cooling and filtering the concentrated leachate, and the filtrate is put into a vacuum cooker, and the mixture is heated under reduced pressure with appropriate stirring at a temperature of 60 to 70°C. During further concentration, 4.5 kg of corn starch and 200 g of lactose were added as excipients to form a clay-like mixture, and the clay-like mixture was formed into granules using a granulator.
ついで、若干の湿気を含む上記顆粒を乾燥機で
乾燥して、生薬乾燥エキス:3Kgと賦形剤:4.5
Kgからなる顆粒剤7.5Kgを調製した後、これを計
量包装機により、3000個のアルミ箔製の小袋の中
に均等に分配し、封入して、1包当り生薬乾燥エ
キス:1gと賦形剤:1.5gからなる顆粒状の本
発明治療薬が前記小袋に2.5gずつ封入されてい
る包みを3000包製造した。 Next, the granules containing some moisture were dried in a dryer to obtain 3 kg of dried herbal medicine extract and 4.5 kg of excipients.
After preparing 7.5 kg of granules, it is evenly distributed into 3000 aluminum foil sachets using a weighing and packaging machine, sealed, and each bag contains 1 g of dried crude drug extract and excipients. Agent: 3,000 sachets were manufactured in which each sachet contained 2.5 g of the granular therapeutic agent of the present invention each containing 1.5 g.
つぎに、このようにして製造された本発明治療
薬の薬効を評価するため、以下の臨床試験を実施
した。 Next, in order to evaluate the efficacy of the therapeutic agent of the present invention thus produced, the following clinical test was conducted.
(1) 歯科医療事務員として歯科医院に勤務してい
るうちに、精神的な緊張から胃炎を起した後、
5か月間市販の胃腸薬を服用したが、さつぱり
快方に向かわないため専門医に受診して、レン
トゲン検査の結果神経性胃炎と診断され、医師
の指示により従来の治療薬の服用、食事療法、
運動療法および安定した精神生活療法等を続け
ていた患者(女子、26才)に対し、上記従来の
治療薬の代わりに本発明治療薬を、1日目に2
包、(朝食後1包、昼食後および夕食後にそれ
ぞれ0.5包)、2〜5日目に1日当り1.5包ずつ
(毎食後0.5包ずつ3回)服用させたところ、そ
れまでに患者が訴えていた胃痛、胸やけ、めま
い、吐き気等の症状が無くなつた。(1) While working at a dental clinic as a dental medical clerk, he developed gastritis due to mental stress.
I took over-the-counter gastrointestinal medicine for five months, but I felt no improvement, so I went to see a specialist and was diagnosed with neurogenic gastritis as a result of an X-ray examination.As per the doctor's instructions, I started taking conventional medicine and eating. therapy,
A patient (female, 26 years old) who was continuing exercise therapy and stable mental lifestyle therapy, was given two doses of the therapeutic drug of the present invention on the first day instead of the conventional therapeutic drug mentioned above.
(1 packet after breakfast, 0.5 packets each after lunch and dinner), and 1.5 packets per day on days 2 to 5 (3 times of 0.5 packets after each meal). Symptoms such as stomach pain, heartburn, dizziness, and nausea disappeared.
その後引続き6〜20日目まで上記と同様に1
日当り1.5包ずつ服用した後、医師の指示によ
り本発明治療薬の服用を中止し、規則正しい生
活、適正な食事療法、運動療法および安定した
精神生活療法を続けたところ、本剤の服用を開
始してから30日後には、上記治療を施さなくて
も正常人と変わらない健康状態を維持すること
ができ、自然治癒に至つた。 After that, continue 1 as above from 6th to 20th day.
After taking 1.5 sachets per day, I stopped taking the therapeutic agent of the present invention according to the doctor's instructions, and continued to live a regular life, have a proper diet, exercise therapy, and maintain a stable mental lifestyle, and then started taking this drug. After 30 days, the patient was able to maintain a healthy condition similar to that of a normal person even without the above treatment, and spontaneous recovery was achieved.
(2) 食後や空腹時に、もたれ、張り、重苦しさの
ような不快感や痛みを胃部に感じる上に、げつ
ぷ、胸やけ、めまい、疲労感および口臭等の症
状を起こし、レントゲン検査および内視鏡検査
の結果慢性胃炎と診断されて、医師の指示によ
る従来の薬物療法と仕事を続けている、発病後
約7カ月を経過している患者(男子、42才)に
対し、従来の治療薬の代りに本発明治療薬を、
前記と同様に、すなわち1日目に2包、2〜5
日目に1日当り1.5包ずつ服用させたところ、
上記の諸症状は消え去り、その後引続き6〜25
日目まで同様に1日当り1.5包ずつ服用した後、
医師の指示により本発明治療薬の服用を中止
し、食事療法、運動療法および規則正しい生活
を続けたところ、本剤の服用を開始してから40
日後には、上記治療を施さなくても正常人と変
わらない健康状態を維持することができ、病気
は自然に治癒した。(2) After eating or on an empty stomach, you may feel discomfort or pain in your stomach, such as heaviness, tightness, or heaviness, as well as symptoms such as burping, heartburn, dizziness, fatigue, and bad breath, which may cause X-ray examination. A patient (male, 42 years old) who has been diagnosed with chronic gastritis as a result of endoscopy and who is continuing to work and take conventional drug therapy as prescribed by his doctor, and who has been diagnosed with chronic gastritis for about 7 months since the onset of his illness. The therapeutic agent of the present invention instead of the therapeutic agent of
Same as above, i.e. 2 sachets on the 1st day, 2-5
When I took 1.5 packets per day on the first day,
The symptoms mentioned above disappeared and then continued for 6 to 25 days.
After taking 1.5 packets per day in the same way until day 1,
After discontinuing taking the therapeutic agent of the present invention under the doctor's instructions and continuing diet therapy, exercise therapy, and a regular lifestyle, 40 days after starting to take this drug.
After a few days, the patient was able to maintain the same health status as a normal person without the above treatment, and the disease healed naturally.
(3) 職責上のストレスの蓄積と不規則な生活様式
の繰返しによつて、常時胃部の痛みと不快感、
胸やけ、全身的疲労感、焦燥感、めまいを生
じ、発病後約5か月を経過して、レントゲン検
査の結果神経性胃炎と診断されて、医師の指示
による従来の治療薬の服用と会社勤務を続けて
いる患者(男子、50才)に対し、上記従来の治
療薬の代わりに本発明治療薬を、前記と同じ服
用量で、すなわち1日目に2包、2〜5日目に
1日当り1.5包ずつ服用させたところ、上記の
諸症状は無くなり、その後引続いて6〜20日目
まで同様に1日当り1.5包ずつ服用させた後、
医師の指示により本発明治療薬の服用を中止
し、適当な食生活と運動、および規則正しい生
活に留意しながら安定した精神生活療法を施し
たところ、本剤の服用を開始してから30日後に
は、上記治療を施さなくても正常人と変わらな
い健康状態を維持することができ、病気は完全
に治癒した。(3) Constant pain and discomfort in the stomach due to accumulated stress from work and repeated irregular lifestyles.
I developed heartburn, general fatigue, irritability, and dizziness.About 5 months after the onset of the disease, an X-ray examination revealed that I had neurogenic gastritis.I started taking conventional treatment medications as directed by my doctor, and the company For a patient (male, 50 years old) who continues to work, the therapeutic agent of the present invention was administered in place of the above-mentioned conventional therapeutic agent at the same dosage as above, i.e., 2 sachets on the 1st day and on the 2nd to 5th days. When I took 1.5 packets per day, the above symptoms disappeared, and I continued to take 1.5 packets per day from 6th to 20th day.
As per the doctor's instructions, I stopped taking the drug of this invention and started stable mental lifestyle therapy while paying attention to proper diet, exercise, and a regular lifestyle, and 30 days after I started taking this drug. was able to maintain a state of health comparable to that of a normal person even without the above treatment, and the disease was completely cured.
(4) 食後直ちに下腹部痛を起こす上に、腹部にガ
スがたまつて腹が張り、腸がゴロゴロ鳴る一
方、動悸、頭痛、めまいおよび不眠等の症状を
現わし、レントゲン検査の結果慢性化した腸炎
にかかつていると診断されて、直ちに医師の指
示により従来の治療薬の服用、食事療法および
安定した精神生活療法を続けながら会社に勤務
中の患者(男子、47才)に対し、上記従来の治
療薬の代りに本発明治療薬を、1〜5日目に1
日当り2包ずつ(朝食後1包、昼食後および夕
食後にそれぞれ0.5包)、また6〜10日目に1.5
包ずつ(毎食後0.5包)服用させたところ、下
腹部痛、腸のゴロゴロ、動悸、頭痛、めまい、
不眠の症状が改善され、神経のイライラも無く
なつて、約3か月間続いた不快感が解消され
た。(4) In addition to causing lower abdominal pain immediately after eating, gas accumulates in the abdomen and makes the stomach bloat, and the intestines make rumbling sounds, while symptoms such as palpitations, headache, dizziness, and insomnia appear, and X-ray examination shows that the condition is chronic. The patient (male, 47 years old), who was diagnosed with enteritis and was currently working at a company while continuing to take conventional medications, diet, and stable mental lifestyle therapy under the instructions of a doctor, was given the above treatment. The therapeutic agent of the present invention was administered once on days 1 to 5 instead of the conventional therapeutic agent.
2 sachets per day (1 sachet after breakfast, 0.5 sachets each after lunch and dinner), and 1.5 sachets on days 6 to 10.
When I took each sachet (0.5 sachets after each meal), I experienced lower abdominal pain, rumbling in the intestines, palpitations, headache, dizziness,
The symptoms of insomnia were improved, the nervous irritation disappeared, and the discomfort that had lasted for about three months disappeared.
その後引続き11〜15日目まで同様に1日当り
1.5包ずつ服用させた後、医師の指示により本
発明治療薬の服用を中止し、食事療法、適当な
運動および精神生活療法を続けたところ、本剤
の服用を開始してから30日後には、上記治療を
施さなくても正常人と変わらない健康状態を維
持することができ、病気は自然治癒した。 After that, continue in the same way from day 11 to day 15.
After taking 1.5 packets each, we stopped taking the therapeutic agent of the present invention according to the doctor's instructions, and continued diet therapy, appropriate exercise, and mental lifestyle therapy. Even without the above treatment, the patient was able to maintain a state of health similar to that of a normal person, and the disease was cured naturally.
(5) 職務上のストレスを受けながら連日にわたつ
て不規則な生活を繰り返すことによつて突然吐
血し、レントゲン検査および内視鏡検査の結果
初期の胃潰瘍にかかつていると診断されて、医
師の指示による従来の内科的治療としての薬物
療法を続けている患者(男子、52才)に対し、
従来の治療薬の代わりに本発明治療薬を、1〜
3日目に1日当り3包ずつ(毎食後それぞれ1
包)、引続き4〜20日目に1日当り1.5包ずつ
(毎食後それぞれ0.5包)服用させたところ、み
ずおちの痛み、胸やけ、胃酸過多、嘔吐等の諸
症状が無くなり、その後医師の指示により本発
明治療薬の服用を中止し、専ら心身の安静、ス
トレスの回避、および食人療法による胃の庇護
に努めたところ、本剤の服用を開始してから60
日後には、潰瘍部位は完全に治癒されて、もと
の健康状態に戻つた。(5) As a result of repeatedly leading an irregular lifestyle under the stress of work, I suddenly started coughing up blood, and as a result of X-ray and endoscopy tests, I was diagnosed with an early gastric ulcer, and a doctor For a patient (male, 52 years old) who continues to receive drug therapy as a conventional medical treatment under the direction of
The therapeutic agent of the present invention is used in place of the conventional therapeutic agent, from 1 to
On the 3rd day, take 3 sachets per day (1 each after each meal)
When I continued to take 1.5 sachets per day (0.5 sachets each after each meal) from 4th to 20th day, the symptoms such as water rash pain, heartburn, hyperacidity, and vomiting disappeared, and after that, as per the doctor's instructions. After discontinuing taking the therapeutic drug of the present invention, I focused on resting my mind and body, avoiding stress, and protecting my stomach through cannibal therapy.
After a few days, the ulcer site was completely healed and returned to its original state of health.
(6) 空腹時や夜間、早朝に腹部に激痛があり、ま
た著しい胸やけおよび腹部の不快感を起こして
いたためにレントゲン検査および内視鏡検査を
受けたところ、初期の十二指腸潰瘍にかかつて
いると診断されて、医師の指示による従来の内
科的治療としての薬物療法を続けている患者
(男子、45才)に対し、従来の治療薬の代わり
に本発明治療薬を、前記と同様に1〜5日目に
1日当り3包ずつ、また6〜30日目に1日当り
1.5包ずつ服用させたところ、痛みや胸やけお
よび腹部の不快感が無くなり、その後医師の指
示により本発明治療薬の服用を中止し、食事療
法、規則正しい生活、ストレスの回避および精
神の安定に努めたところ、本剤の服用を開始し
てから95日後には、上記の治療を格別施さなく
てももとの健康状態に戻り、潰瘍部位は完全に
治癒されるに至つた。(6) The patient had severe pain in the abdomen when fasting, at night, and early in the morning, and was also experiencing severe heartburn and abdominal discomfort, which led to an X-ray examination and endoscopy, which revealed that he had an early duodenal ulcer. A patient (male, 45 years old) who was diagnosed with the disease and continues to take conventional drug therapy as a medical treatment under the direction of a doctor, was given the therapeutic drug of the present invention in place of the conventional therapeutic drug in the same manner as above. ~3 sachets per day on the 5th day, and 3 sachets per day on the 6th to 30th days
After taking 1.5 sachets at a time, the pain, heartburn, and abdominal discomfort disappeared.Thereafter, as per the doctor's instructions, the patient stopped taking the therapeutic agent of the present invention and continued to maintain a regular diet, avoid stress, and maintain mental stability. However, 95 days after starting to take this drug, the patient returned to his original state of health without any special treatment, and the ulcer site was completely healed.
(7) 毎食後に起こるみずおち部位の痛みと、背中
から左肩までひびく激痛のためレントゲン検査
および内視鏡検査を受けたところ、中期の胃潰
瘍にかかつていると診断されて、医師の指示に
よる従来の内科的治療としての薬物療法を続け
ている患者(女子、66才)に対し、従来の治療
薬の代わりに本発明治療薬を、前記と同様に1
〜5日目に1日当り3包ずつ、また6〜40日目
に1日当り1.5包ずつ服用させたところ、痛み、
吐き気、胸やけ等が無くなり、その後医師の指
示により本発明治療薬の使用を中止し、食事療
法を中心として心身の安静、ストレスの回避に
努めたところ、本剤の服用を開始してから120
日後には、上記の治療を施さなくてももとの健
康状態に戻り、潰瘍部位は完全に治療されるに
至つた。(7) Because of the pain in my water lining after every meal and the severe pain that radiated from my back to my left shoulder, I underwent an X-ray examination and an endoscopy, and was diagnosed with a mid-stage gastric ulcer. For a patient (female, 66 years old) who is continuing drug therapy as a medical treatment, the therapeutic agent of the present invention was administered in the same manner as above in place of the conventional therapeutic agent.
When I took 3 sachets per day on the 5th day and 1.5 sachets per day on the 6th to 40th days, I experienced pain,
After my nausea, heartburn, etc. disappeared, I stopped using the therapeutic agent of this invention based on the doctor's instructions, and tried to rest my mind and body mainly through diet therapy and avoid stress.
After a few days, the patient returned to his previous state of health without the above treatment, and the ulcer site was completely healed.
[発明の総合的効果]
以上述べた説明から明らかなように、この発明
によると、胃腸病に基づく痛み、下痢、便秘、悪
心、胸やけ、食欲不振、腹部膨満感等の症状が速
やかに軽減ないし除去されるばかりでなく、胃腸
病、特にストレスに起因する胃炎や腸炎、および
胃・十二脂腸潰瘍に対してすぐれた薬効を発揮し
て、これらの病気の根本的な治療を導くことがで
き、しかも長時間の服用によつても副作用を全く
起こさない胃腸病治療薬およびその製造方法が提
供される。[Overall Effects of the Invention] As is clear from the above explanation, according to the present invention, symptoms such as pain, diarrhea, constipation, nausea, heartburn, loss of appetite, and abdominal bloating caused by gastrointestinal diseases are rapidly alleviated. In addition to being effective in treating gastrointestinal diseases, especially stress-induced gastritis and enteritis, as well as gastric and duodenal ulcers, it is possible to lead to the fundamental treatment of these diseases. To provide a therapeutic drug for gastrointestinal diseases which can be used for a long period of time and which does not cause any side effects even when taken for a long period of time, and a method for producing the same.
Claims (1)
部と、 カンゾウ(同、甘草):2.5〜25重量部との配合
割合の生薬から抽出された生薬エキスを有効成分
として含有する胃腸病治療薬。 2 カキドウシ(生薬名、連銭草):3〜30重量
部と、 カンゾウ(同、甘草):2.5〜25重量部との配合
割合の生薬を300〜900重量部の水とともに加熱煮
沸して前記生薬の有効成分を熱湯中に浸出させな
がら、その浸出液を、前記水の量がほぼ半量以下
ないし6分の1となるまで蒸発濃縮した後、この
ようにして得られた濃縮液を製剤することを特徴
とする、前記生薬から抽出された生薬エキスを有
効成分として含有する胃腸病治療薬の製造方法。[Scope of Claims] 1. An effective crude drug extract extracted from crude drugs in a blending ratio of 3 to 30 parts by weight of Kakidou (herbal medicine name, Renzenso) and 2.5 to 25 parts by weight of Licorice (licorice root). A drug for treating gastrointestinal diseases that contains it as an ingredient. 2. A crude drug containing 3 to 30 parts by weight of Kakidou (herbal medicine name, Renzenso) and 2.5 to 25 parts by weight of Licorice (licorice) is heated and boiled with 300 to 900 parts by weight of water, and then The active ingredients of the crude drug are leached into boiling water, and the leached liquid is evaporated and concentrated until the amount of the water becomes approximately half or less to one-sixth, and then the concentrated liquid thus obtained is formulated. A method for producing a drug for treating gastrointestinal diseases, which contains as an active ingredient a crude drug extract extracted from the crude drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62192307A JPS6438025A (en) | 1987-07-31 | 1987-07-31 | Remedy for gastrointestinal disease and production thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62192307A JPS6438025A (en) | 1987-07-31 | 1987-07-31 | Remedy for gastrointestinal disease and production thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6438025A JPS6438025A (en) | 1989-02-08 |
| JPH0476972B2 true JPH0476972B2 (en) | 1992-12-07 |
Family
ID=16289095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62192307A Granted JPS6438025A (en) | 1987-07-31 | 1987-07-31 | Remedy for gastrointestinal disease and production thereof |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6438025A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100418065B1 (en) * | 2000-08-22 | 2004-02-11 | 주식회사 뉴로넥스 | Use of liquiritigenin or isoliquiritigenin as an antagonist for histamine H2 receptors |
-
1987
- 1987-07-31 JP JP62192307A patent/JPS6438025A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6438025A (en) | 1989-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5023245A (en) | Improved niacin formulation | |
| JPS63290830A (en) | Composition and method of treating gastro-intestinal disease | |
| JPH0625064B2 (en) | Controlled release potassium chloride | |
| JP3018160B2 (en) | Drug for reducing dysmenorrhea and / or premenstrual syndrome | |
| JPS61183220A (en) | Analgesic medicinal composition, manufacture and use | |
| CN101411851B (en) | A traditional Chinese medicine composition for preventing and treating hyperlipidemia and atherosclerosis | |
| WO1992022307A1 (en) | Remedy for chronic fatigue syndrome | |
| CN101590031B (en) | preparation method of disodium sulfodehydroabietate (DSDA) and composition | |
| US4515802A (en) | Analgesic preparations | |
| JPH0476972B2 (en) | ||
| CN105169290A (en) | Traditional Chinese medicine composition for treating primary trigeminal neuralgia and application thereof | |
| JP2006131555A (en) | Antacid composition | |
| JP2008056567A (en) | Medicament for treatment or prevention of gastrointestinal diseases | |
| CN102526639A (en) | Chinese medicinal composition for treating hyperlipidemia and preparation method thereof | |
| CN115554345B (en) | A Chinese medicinal compound preparation for treating gout and hyperuricemia, and its preparation method | |
| CN1077431C (en) | Mediodespidine | |
| GB2135884A (en) | Analgesic preparations containing tizanidine and paracetamol | |
| GB2175804A (en) | Treating cramp | |
| JPS63192722A (en) | Remedy for diabetes and production thereof | |
| CN1088378C (en) | Oral Chinese medicine liquid for treating chronic superficial gastritis and its preparation | |
| CN101716202B (en) | Traditional Chinese medicine containing radix achyranthis bidentatae for treating facioplegia as well as preparation method and use | |
| CN1220508C (en) | Medicine for curing diseases of digestive system and its preparation method | |
| JPH01132531A (en) | Preventive for cancer and production thereof | |
| CN105944089A (en) | Capsule for treating atrophic gastritis and preparation method thereof | |
| CN1064533C (en) | Compound capsule for treating red swollen and heat-evil due to wind-cold-dampness |